"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 4 | 11 | 15 |
| 1997 | 4 | 6 | 10 |
| 1998 | 6 | 16 | 22 |
| 1999 | 10 | 18 | 28 |
| 2000 | 7 | 12 | 19 |
| 2001 | 13 | 20 | 33 |
| 2002 | 11 | 14 | 25 |
| 2003 | 15 | 16 | 31 |
| 2004 | 23 | 16 | 39 |
| 2005 | 25 | 18 | 43 |
| 2006 | 26 | 16 | 42 |
| 2007 | 30 | 13 | 43 |
| 2008 | 20 | 19 | 39 |
| 2009 | 30 | 19 | 49 |
| 2010 | 35 | 21 | 56 |
| 2011 | 19 | 11 | 30 |
| 2012 | 17 | 11 | 28 |
| 2013 | 18 | 8 | 26 |
| 2014 | 17 | 12 | 29 |
| 2015 | 13 | 8 | 21 |
| 2016 | 15 | 7 | 22 |
| 2017 | 27 | 11 | 38 |
| 2018 | 24 | 15 | 39 |
| 2019 | 17 | 10 | 27 |
| 2020 | 15 | 15 | 30 |
| 2021 | 12 | 19 | 31 |
| 2022 | 4 | 24 | 28 |
| 2023 | 4 | 18 | 22 |
| 2024 | 16 | 7 | 23 |
| 2025 | 12 | 7 | 19 |
| 2026 | 5 | 2 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Monoclonal antibodies inhibiting MMP-9 activity alleviate peripheral neuropathy in diabetic mice. Sci Transl Med. 2026 Sep 09; 18(866):eadw3558.
-
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE. Blood Adv. 2026 07 14; 10(13):4541-4550.
-
Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial. J Crohns Colitis. 2026 Jul 07; 20(7).
-
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med. 2026 Apr 02; 394(13):1257-1269.
-
Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis. Adv Ther. 2026 03; 43(3):1016-1033.
-
Pediatric Infectious Diseases Physicians' Preferences for Management of Clostridioides difficile Infection: An Emerging Infections Network Survey. J Pediatric Infect Dis Soc. 2026 Jan 17; 15(1).
-
SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement. Br J Dermatol. 2026 01 06; 194(1):25-36.
-
Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists. Clin Genitourin Cancer. 2026 Mar; 24(2):102487.
-
An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer. Cancer Res. 2025 11 14; 85(22):4521-4540.
-
Enhanced In Vivo Tetanus Toxin Neutralizing Potency of an Anti-Toxin Monoclonal Antibody Following Antibody Chimerization. J Biochem Mol Toxicol. 2025 Nov; 39(11):e70595.